RETN and obesity disorder: Considering the capability of CX-4945 to decrease the expression levels of pathogenic leptin and resistin during 3T3-L1 preadipocyte differentiation, it is suggested that CX-4945 may be used as a potential anti-obesity drug candidate or hit to target obesity and related diseases in which overexpression of leptin and resistin is problematic.